Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.

Garrison LP Jr, Zamora B, Li M, Towse A.

J Manag Care Spec Pharm. 2020 Apr;26(4):400-406. doi: 10.18553/jmcp.2020.26.4.400.

2.

Development of a Sleep Apnea-Specific Health State Utility Algorithm.

Skirko JR, James KT, Garrison LP, Weaver EM.

JAMA Otolaryngol Head Neck Surg. 2020 Jan 30. doi: 10.1001/jamaoto.2019.4469. [Epub ahead of print]

PMID:
31999308
3.

Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.

Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP Jr.

J Med Econ. 2020 Feb 13:1-12. doi: 10.1080/13696998.2020.1721508. [Epub ahead of print]

PMID:
31971453
4.

Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention.

Hart MR, Garrison LP Jr, Doyle DL, Jarvik GP, Watkins J, Devine B.

Value Health. 2019 Nov;22(11):1231-1239. doi: 10.1016/j.jval.2019.05.015. Epub 2019 Oct 16.

PMID:
31708059
5.

Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.

Garrison LP Jr, Neumann PJ, Willke RJ.

J Manag Care Spec Pharm. 2019 Nov;25(11):1185-1192. doi: 10.18553/jmcp.2019.25.11.1185.

6.

A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine.

Garrison LP Jr, Towse A.

J Manag Care Spec Pharm. 2019 Oct;25(10):1082-1087. doi: 10.18553/jmcp.2019.25.10.1082.

7.

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.

Yu PP, Eton O, Garrison LP.

J Immunother Cancer. 2019 Sep 3;7(1):235. doi: 10.1186/s40425-019-0707-9.

8.

How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.

Li M, Basu A, Bennette C, Veenstra D, Garrison LP Jr.

Value Health. 2019 Jul;22(7):777-784. doi: 10.1016/j.jval.2019.02.002. Epub 2019 May 17.

PMID:
31277824
9.

Do cancer treatments have option value? Real-world evidence from metastatic melanoma.

Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP.

Health Econ. 2019 Jul;28(7):855-867. doi: 10.1002/hec.3899.

PMID:
31237095
10.

Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework.

Garrison LP Jr, Jansen JP, Devlin NJ, Griffin S.

Value Health. 2019 Jun;22(6S):S12-S17. doi: 10.1016/j.jval.2019.04.1915. No abstract available.

PMID:
31200801
11.

Defining and Managing High-Priced Cures: Healthcare Payers' Opinions.

Yeung K, Suh K, Garrison LP Jr, Carlson JJ.

Value Health. 2019 Jun;22(6):648-655. doi: 10.1016/j.jval.2018.11.012. Epub 2019 May 17.

PMID:
31198181
12.

Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya.

Vodicka EL, Chung MH, Zimmermann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Stergachis A, Garrison LP Jr, Babigumira JB.

PLoS One. 2019 Jun 6;14(6):e0217331. doi: 10.1371/journal.pone.0217331. eCollection 2019.

13.

Determinants of specialist physician ambulatory visits: a neurology example.

van der Goes DN, Ney JP, Garrison LP.

J Med Econ. 2019 Aug;22(8):830-839. doi: 10.1080/13696998.2019.1618861. Epub 2019 Jun 18.

PMID:
31081729
14.

Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.

Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr.

J Med Econ. 2019 Oct;22(10):1006-1013. doi: 10.1080/13696998.2019.1614933. Epub 2019 May 20.

PMID:
31050315
15.

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.

Garrison LP Jr, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA.

Value Health. 2019 Apr;22(4):408-415. doi: 10.1016/j.jval.2018.11.014. Epub 2019 Mar 11. Erratum in: Value Health. 2019 Jul;22(7):843.

PMID:
30975391
16.

Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.

Garrison LP, Jackson T, Paul D, Kenston M.

J Manag Care Spec Pharm. 2019 Jul;25(7):793-799. doi: 10.18553/jmcp.2019.18378. Epub 2019 Feb 20.

17.

Value-Based Pricing in Latin America: How Far Away Are We?

Mejía A, Gilardino R, Kristensen FB, Garrison LP; ISPOR Health Technology Assessment Latin America Roundtable.

Value Health Reg Issues. 2018 Dec;17:219-223. doi: 10.1016/j.vhri.2018.09.007. Epub 2018 Dec 6.

PMID:
30528780
18.

Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.

Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL.

Value Health. 2018 Oct;21(10):1133-1149. doi: 10.1016/j.jval.2018.08.005. Review. Erratum in: Value Health. 2019 Mar;22(3):383. Value Health. 2019 Apr;22(4):502.

PMID:
30314613
19.

Cost-Effectiveness of Strategies for the Diagnosis and Treatment of Febrile Illness in Children.

Babigumira JB, Gelband H, Garrison LP Jr..

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 15.

20.

Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.

Zimmermann M, Vodicka E, Holman AJ, Garrison LP Jr.

J Med Econ. 2018 Jul;21(7):712-720. doi: 10.1080/13696998.2018.1470519. Epub 2018 May 11.

PMID:
29701508

Supplemental Content

Loading ...
Support Center